Bb Biotech Ag decreased its stake in Celgene Corp (CELG) by 4.16% based on its latest 2016Q3 regulatory filing with the SEC. Bb Biotech Ag sold 150,000 shares as the company’s stock rose 3.80% with the market. The institutional investor held 3.46M shares of the major pharmaceuticals company at the end of 2016Q3, valued at $361.60M, down from 3.61M at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Celgene Corp for a number of months, seems to be less bullish one the $92.83 billion market cap company. The stock closed at $119.98 during the last session. It is down 11.71% since June 7, 2016 and is uptrending. It has outperformed by 4.29% the S&P500.
Bb Biotech Ag, which manages about $2.84B US Long portfolio, upped its stake in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 40,000 shares to 245,000 shares, valued at $98.50M in 2016Q3, according to the filing. It also increased its holding in Macrogenics Inc. (NASDAQ:MGNX) by 935,000 shares in the quarter, for a total of 1.46M shares, and has risen its stake in Agios Pharmaceuticals Inc. (NASDAQ:AGIO).
Insitutional Activity: The institutional sentiment increased to 1.11 in Q3 2016. Its up 0.12, from 0.99 in 2016Q2. The ratio improved, as 42 funds sold all CELG shares owned while 426 reduced positions. 127 funds bought stakes while 391 increased positions. They now own 578.10 million shares or 1.55% less from 587.22 million shares in 2016Q2. Delta Lloyd Nv has 57,591 shares for 0.19% of their US portfolio. Boston Prtnrs has invested 0.03% of its portfolio in Celgene Corporation (NASDAQ:CELG). Hsbc Public Limited Liability Company has 620,871 shares for 0.16% of their US portfolio. Ridgeworth Management Limited Liability reported 824 shares or 0% of all its holdings. Muhlenkamp And last reported 73,515 shares in the company. Nomura holds 75,372 shares or 0.02% of its portfolio. Gp One Trading LP owns 27,053 shares or 0.03% of their US portfolio. Bancshares Pictet And Cie (Asia) Limited last reported 10,430 shares in the company. Adams Asset Advisors Limited Liability Company holds 0.12% or 8,500 shares in its portfolio. Sumitomo Mitsui Tru reported 2.32 million shares or 0.4% of all its holdings. Reynders Mcveigh Cap Mgmt Lc has invested 0.1% of its portfolio in Celgene Corporation (NASDAQ:CELG). Mizuho Trust Company Limited has 1.24M shares for 0.38% of their US portfolio. Wealth Enhancement Advisory holds 0.09% or 5,904 shares in its portfolio. Birch Hill Investment Limited Liability Corporation holds 333,813 shares or 3.24% of its portfolio. Buffington Mohr Mcneal has invested 0.88% of its portfolio in Celgene Corporation (NASDAQ:CELG).
Insider Transactions: Since July 28, 2016, the stock had 0 buys, and 11 sales for $46.90 million net activity. The insider HUGIN ROBERT J sold $11.00M. The insider MARIO ERNEST sold 15,000 shares worth $1.64 million. CASEY MICHAEL D had sold 43,134 shares worth $4.92 million. BARKER RICHARD W sold $2.22 million worth of stock. VESSEY RUPERT also sold $307,950 worth of Celgene Corporation (NASDAQ:CELG) on Tuesday, November 22. PEHL MICHAEL F. also sold $2.67 million worth of Celgene Corporation (NASDAQ:CELG) on Thursday, November 10. The insider Friedman Michael A sold $5.82 million.
Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 26. They expect $1.42 EPS, up 42.00% or $0.42 from last year’s $1 per share. CELG’s profit will be $1.10 billion for 21.12 P/E if the $1.42 EPS becomes a reality. After $1.39 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 2.16% EPS growth.
More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Investorplace.com which released: “Trade of the Day: Celgene Corporation (CELG) Stock Keeps Growing” on January 11, 2017, also Finance.Yahoo.com with their article: “Celgene Corporation Announces Preliminary 2016 Unaudited Results and 2017 …” published on January 09, 2017, Seekingalpha.com published: “Should You Own Celgene In 2017? Part 1” on January 10, 2017. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Fool.com and their article: “3 Biggest Risks for Celgene Corporation” published on December 15, 2016 as well as Fool.com‘s news article titled: “Better Buy: Celgene Corporation vs. Johnson & Johnson” with publication date: December 19, 2016.
According to Zacks Investment Research, “Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.”
Celgene Corporation (NASDAQ:CELG) Ratings Coverage
Out of 22 analysts covering Celgene Corporation (NASDAQ:CELG), 18 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 82% are positive. Celgene Corporation has been the topic of 39 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Jefferies initiated the shares of CELG in a report on Wednesday, September 9 with “Buy” rating. Suntrust Robinson maintained the shares of CELG in a report on Friday, April 29 with “Buy” rating. RBC Capital Markets maintained Celgene Corporation (NASDAQ:CELG) rating on Friday, January 29. RBC Capital Markets has “Outperform” rating and $135 price target. BTIG Research upgraded Celgene Corporation (NASDAQ:CELG) on Thursday, August 4 to “Buy” rating. The rating was initiated by Credit Suisse on Wednesday, January 20 with “Outperform”. The company was maintained on Friday, July 24 by Cantor Fitzgerald. The firm has “Buy” rating given on Friday, November 6 by Canaccord Genuity. On Thursday, January 14 the stock rating was initiated by Standpoint Research with “Buy”. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, April 19. On Thursday, February 25 the stock rating was initiated by Citigroup with “Buy”.
CELG Company Profile
Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.